Ventricular function and tissue characterization by cardiac magnetic resonance imaging following hospitalization for multisystem inflammatory syndrome in children: a prospective study
暂无分享,去创建一个
Kanwal M. Farooqi | D. Farber | T. Connors | U. Krishnan | E. Rosenzweig | M. Dilorenzo | Amee M. Shah | J. Milner | J. Harrington | B. Anderson | M. Gorelik | Rachel Weller | Anne Ferris | A. Channing | Karen Martirosyan | Rachel J Weller | Anne M. Ferris
[1] G. Di Salvo,et al. Myocardial involvement in children with post-COVID multisystem inflammatory syndrome: a cardiovascular magnetic resonance based multicenter international study—the CARDOVID registry , 2021, Journal of Cardiovascular Magnetic Resonance.
[2] H. Seiden,et al. Mid-Term Outcomes and Cardiac Magnetic Resonance Imaging Following Multisystem Inflammatory Syndrome in Children. , 2021, The Journal of pediatrics.
[3] R. Friedman,et al. Six Month Follow-up of Patients With Multi-System Inflammatory Syndrome in Children , 2021, Pediatrics.
[4] G. Di Salvo,et al. Early Echocardiographic and Cardiac MRI Findings in Multisystem Inflammatory Syndrome in Children , 2021, Journal of clinical medicine.
[5] Kanwal M. Farooqi,et al. Longitudinal Outcomes for Multisystem Inflammatory Syndrome in Children , 2021, Pediatrics.
[6] K. Rychlik,et al. Cardiovascular magnetic resonance imaging in children after recovery from symptomatic COVID-19 or MIS-C: a prospective study , 2021, Journal of Cardiovascular Magnetic Resonance.
[7] S. Kabir,et al. Multimodality cardiac evaluation in children and young adults with multisystem inflammation associated with COVID-19 , 2020, European heart journal cardiovascular Imaging.
[8] P. Zachariah,et al. Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents in New York City. , 2020, JAMA.
[9] F. Rovida,et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review. , 2020, JAMA pediatrics.
[10] Matthias Gutberlet,et al. Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. , 2018, Journal of the American College of Cardiology.
[11] Richard B. Thompson,et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI) , 2017, Journal of Cardiovascular Magnetic Resonance.
[12] D. Messroghli,et al. Myocardial T1 Mapping in Pediatric and Congenital Heart Disease , 2015, Circulation. Cardiovascular imaging.
[13] M. Robson,et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement , 2013, Journal of Cardiovascular Magnetic Resonance.
[14] Andrew S Flett,et al. Comprehensive Validation of Cardiovascular Magnetic Resonance Techniques for the Assessment of Myocardial Extracellular Volume , 2013, Circulation. Cardiovascular imaging.
[15] P. Kellman,et al. Association Between Extracellular Matrix Expansion Quantified by Cardiovascular Magnetic Resonance and Short-Term Mortality , 2012, Circulation.
[16] M. Hayward,et al. Equilibrium Contrast Cardiovascular Magnetic Resonance for the Measurement of Diffuse Myocardial Fibrosis: Preliminary Validation in Humans , 2010, Circulation.
[17] Clare Jackson,et al. Journal of Cardiovascular Magnetic Resonance Open Access Normal Right-and Left Ventricular Volumes and Myocardial Mass in Children Measured by Steady State Free Precession Cardiovascular Magnetic Resonance , 2009 .
[18] S. Chugh,et al. Gadolinium-enhanced magnetic resonance imaging for detection and quantification of fibrosis in human myocardium in vitro , 2007, The International Journal of Cardiovascular Imaging.
[19] Michael Jerosch-Herold,et al. T1 Mapping: Basic Techniques and Clinical Applications. , 2016, JACC. Cardiovascular imaging.
[20] M. Link,et al. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the American Heart Associat , 2015, Journal of the American College of Cardiology.